GET DAILY SIGNALSLineage Cell Therapeutics (LCTX) Q3 2026 Earnings Preview: Pipeline Focus Over Revenue
Key Takeaways
- Lineage Cell Therapeutics (LCTX) is set to report third quarter 2026 results on November 12, 2026, after U.S. markets close, with a conference call at 4:30 p.m. Eastern Time.
- Consensus estimates call for a net loss of roughly $0.02 per share on revenue of about $2.32 million, compared with $3.68 million in revenue from the same quarter a year ago.
- As a clinical-stage biotechnology company, Lineage draws more investor attention to pipeline progress than to quarterly revenue, which can vary with collaboration-related recognition.
- The OpRegen program, developed with Roche and Genentech for dry age-related macular degeneration (AMD), stands out as the primary item to monitor in the update.
- Cash runway and operating expense management remain important, with prior guidance pointing to funding through 2028.
- For more information on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these pages.
Earnings Context and Why It Matters
Lineage Cell Therapeutics develops allogeneic, or “off-the-shelf,” cell therapies aimed at serious conditions. For a firm with relatively modest and sometimes uneven revenue, the quarterly update serves more as a checkpoint on clinical execution, partnership activity, and financial staying power than a standard earnings scorecard. I find it useful to track the OpRegen cell therapy program for dry age-related macular degeneration (AMD), which is advancing through a collaboration with Roche and Genentech, along with earlier programs in spinal cord injury, hearing loss, and diabetes. The report also provides insight into cash runway and whether development milestones are on track to generate future payments.
Earnings Expectations
Analysts anticipate a net loss of approximately $0.02 per share for the third quarter of 2026. Revenue is expected near $2.32 million, down from the $3.68 million recorded in the year-ago period. That earlier figure included collaboration revenue tied to the Roche and Genentech partnership, which illustrates how Lineage’s top line can shift quarter to quarter. In the second quarter of 2026, the company posted revenue of $1.07 million and a loss of $0.03 per share, missing the consensus estimate of about $0.028 per share. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Investors will likely focus on any commentary about collaboration revenue trends and operating expense control.
Market Reaction and Investor Sentiment
Sentiment ahead of the third quarter 2026 update looks measured, given the stock’s past volatility around earnings and the typical uncertainty surrounding a clinical-stage pipeline. Shares have often shown limited or negative reactions to these releases, partly because headline financial numbers matter less than pipeline disclosures for a development-stage biotechnology company. Key items to watch include the timing of any OpRegen-related milestones or data, the pace of clinical site expansion in the Phase 2a GAlette study, and the path of collaboration revenue. Positive comments on enrollment, manufacturing, or partnership progress could influence sentiment more than the modest revenue and loss figures.
Forward Outlook and Key Factors to Monitor
Looking ahead, the main catalysts center on the OpRegen program and its Roche and Genentech partnership. Updates on the ongoing Phase 2a GAlette study in dry AMD, including patient enrollment and site openings, along with any signals of progress toward future milestones that could trigger collaboration payments, deserve close attention. Beyond OpRegen, the OPC1 spinal cord injury program continues in the DOSED study, while earlier assets such as the ReSonance hearing loss program and the ILT1 manufacturing initiative for Type 1 diabetes may surface as longer-term drivers. On the financial side, cash runway and expense discipline stay central. Management has previously indicated funding into 2028, so confirmation that spending aligns with that view will matter. Revenue often stems from collaboration milestones rather than product sales, so strategic execution and clinical milestones will remain the primary focus.
AI Tools in My Research Process
When preparing for updates like this one from Lineage Cell Therapeutics, I frequently rely on Tickeron’s AI-powered tools to scan sector peers and spot patterns quickly. The AI Screener helps filter biotechnology names by technical signals, fundamentals, and performance metrics, which adds useful context without replacing core fundamental analysis. It has become a regular part of my workflow for earnings-related reviews.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LCTX's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for LCTX turned positive on October 08, 2026. Looking at past instances where LCTX's MACD turned positive, the stock continued to rise in 43 of 50 cases over the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 23, 2026. You may want to consider a long position or call options on LCTX as a result. In 99 of 117 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
LCTX moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for LCTX crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.
Following a +4.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where LCTX advanced for three days, in 158 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 125 of 156 cases where LCTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 66 cases where LCTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 74%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LCTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.276) is normal, around the industry mean (2.904). P/E Ratio (-7.357) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.060) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 37 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. LCTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LCTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, and neurological conditions
Industry Biotechnology
Advertisement